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We recently reported a cell death cascade whereby
cellular stressors activate nitric oxide formation
leading to S-nitrosylation of GAPDH that binds to
Siah and translocates to the nucleus. The nuclear
GAPDH/Siah complex augments p300/CBP-associ-
ated acetylation of nuclear proteins, including p53,
which mediate cell death. We report a 52 kDa cyto-
solic protein, GOSPEL, which physiologically binds
GAPDH, in competition with Siah, retaining GAPDH
in the cytosol and preventing its nuclear transloca-
tion. GOSPEL is neuroprotective, as its overexpres-
sion prevents NMDA-glutamate excitotoxicity while
its depletion enhances death in primary neuron
cultures. S-nitrosylation of GOSPEL at cysteine 47
enhances GAPDH-GOSPEL binding and the neuro-
protective actions of GOSPEL. In intact mice, virally
delivered GOSPEL selectively diminishes NMDA
neurotoxicity. Thus, GOSPEL may physiologically
regulate the viability of neurons and other cells.
INTRODUCTION
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is gen-
erally regarded as a housekeeping glycolytic enzyme. However,
several studies implicate GAPDH in cell signaling (Chuang
et al., 2005; Hara et al., 2006a; Sirover, 1999, 2005). We recently
described a signaling system influencing cell death whereby
diverse cell stressors activate inducible or neuronal nitric oxide
synthase (nNOS) leading to the generation of nitric oxide (NO),
which S-nitrosylates GAPDH (Benhar and Stamler, 2005; Hara
et al., 2005, 2006a). S-nitrosylation abolishes catalytic activity
of the enzyme and confers upon it the ability to bind to Siah, an
E3 ubiquitin ligase. The nuclear localization signal of Siah elicits
nuclear translocation of GAPDH. In the nucleus, GAPDH binds
to the protein acetyltransferase p300/CBP, enhancing its acety-
lationof various targets, includingp53,with subsequent augmen-
tation of cytotoxicity (Sen et al., 2008).This signaling cascade appears to mediate the cytoprotective
actions of the monoamine oxidase inhibitor R-()-deprenyl
(selegiline, hereafter designated deprenyl) as well as non-mono-
amine oxidase inhibiting derivatives (Tatton et al., 2003;Waldme-
ier et al., 2000). At low nanomolar concentrations these drugs
prevent the S-nitrosylation of GAPDH, its binding to Siah, and
nuclear translocation, with neuroprotective actions in cells
and rodent models of Parkinsonism at drug doses as low as
0.01 mg/kg (Hara et al., 2006b). Disruption of the NO-GAPDH-
Siah cascade also blocks neurotoxicity elicited by excess activa-
tion of NMDA (N-methyl-D-aspartate) receptors and mutant
Huntingtin (Bae et al., 2006; Hara et al., 2005).
In the present study, we report a protein interactor of GAPDH,
designated GOSPEL (GAPDH’s competitor of Siah Protein
Enhances Life). Cell stress elicits S-nitrosylation of GOSPEL,
enabling it to bind GAPDH in competition with Siah. The binding
of GOSPEL to GAPDH prevents nuclear translocation of GAPDH
and prevents cyto/neurotoxicity. In intact mice, GOSPEL over-
expression in the cerebral cortex reduces NMDA neurotoxicity.
This neuroprotection reflects GOSPEL’s binding to GAPDH, as
mutant GOSPEL that cannot bind GAPDH displays greater
neurotoxicity. The competition between GOSPEL and Siah for
GAPDH binding may reflect a regulatory system that maintains
cellular homeostasis in response to stressors.
RESULTS
Identification of GOSPEL
In a yeast two-hybrid analysiswith theN-terminal 150aminoacids
of GAPDH and a rat hippocampal cDNA library, we identified 27
positive interactors out of 106 clones, 25 of which represented
various fragments of GAPDH. This presumably reflects the
tendency for this protein to form homotetramers (Carlile et al.,
2000). The two non-GAPDH interactors are a fragment of
GOSPEL and an uncharacterized EST clone (Figure 1A). By
contrast, yeast two-hybrid studies employing the C-terminal
183 amino acids of GAPDH identify Siah, but not GOSPEL (Hara
et al., 2005). After cDNA library screening, we identified the entire
coding frame of GOSPEL. GOSPEL contains 406 amino acids







Figure 1. Identification and Characterization of GOSPEL
(A) Yeast two-hybrid analysis with two GAPDH constructs (amino acids 1–150 or 151–333) and a rat hippocampal cDNA library. The 1–150 amino acid fragment
binds GOSPEL but not Siah.
(B) Tissue distribution of GOSPEL mRNA.
(C) Tissue distribution of GOSPEL protein detected with an immunopurified polyclonal antibody against GOSPEL.
(D) GOSPEL in brain tissues. In situ hybridization reveals high expression of GOSPEL in Purkinje cells of the cerebellum as well as CA1-3 pyramidal and dentate
granule neurons in the hippocampus.
(E) Cellular distribution of GOSPEL. Exogenous GOSPEL in HEK293 cells (GOSPEL-HA detected by anti-HA antibody) and endogenous GOSPEL in PC12 cells
(detected by anti-GOSPEL antibody) are exclusively cytosolic. The scale bar represents 40 mm.stretchofglutamines (seeFigureS1Aavailable online). The intron-
exon structure ofGOSPELsuggests thepossibility of alternatively
spliced isoforms (Figure S1B), although there is high sequence
conservation between rodents and humans (Figure S1C).
Northern blot analysis reveals GOSPEL expression highest
in heart, skeletal muscle, brain, and lung (Figure 1B). Western82 Neuron 63, 81–91, July 16, 2009 ª2009 Elsevier Inc.blot analysis, employing an affinity-purified polyclonal antibody
developed against a recombinant GST-fused GOSPEL, reveals
a similar tissue distribution to that shown by northern blotting
(Figure 1C). In brain, heart, and skeletal muscle, western blots
show an apparent molecular weight for GOSPEL of about
52 kDa, whereas in lung the apparent size is somewhat greater,
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GOSPELabout 55 kDa. Interestingly, tissues such as brain, heart, lung,
and skeletal muscle, which are most enriched in GOSPEL, also
contain the highest levels of GAPDH. In brain, GOSPEL is widely
expressed in neurons, and is especially abundant in neurons that
contain high levels of GAPDH, such as Purkinje cells in the cere-
bellum as well as pyramidal cells of CA1-3 and granule cells of
the dentate gyrus in the hippocampus (Figure 1D).
Weexamined the intracellular localizationofGOSPELby immu-
nofluorescent cell staining with confocal microscopy (Figure 1E).
Overexpressed GOSPEL in HEK293T cells and endogenous
GOSPEL in PC12 cells are both predominantly cytosolic.
GOSPEL S-Nitrosylation Is Required for Binding GAPDH
Wemapped binding sites in GAPDH and GOSPEL by performing
selectivedeletions followedby immunoprecipitation fromHEK293
cells (Figures 2A and 2B; Figures S2A and S2B). We identified
amino acids 160–200ofGOSPELascritical for binding toGAPDH.
In GAPDH, a domain comprising amino acids 80–120 is required
for binding to GOSPEL.
To determine the importance of S-nitrosylation for the interac-
tion of these proteins, we examined the binding of GOSPEL to
GAPDH in extracts of NMDA-treated or untreated cerebral
cortical cultures prepared from wild-type or nNOS knockout
mice (Figures 2C and S2C). It has been demonstrated that
NMDA stimulation of cerebral cortical neurons elicits the genera-
tion of NO from nNOS, leading to S-nitrosylation of various
proteins, including GAPDH (Hara et al., 2005; Takahashi et al.,
2007). A low level of GAPDH-GOSPEL binding is detected in the
absence of NMDA treatment. The NMDA-augmented GAPDH-
GOSPEL protein interaction is markedly reduced in nNOS
knockout cultures. To ascertain whether the requirement for
NO involves GOSPEL, we examined whether GOSPEL can be
S-nitrosylated. In cerebral cortical cultures stimulated with
NMDA,biotin switchassays reveal robust endogenousS-nitrosy-
lation of GOSPEL, which is absent in nNOS knockout cultures
(Figure 2D). The S-nitrosylation of GOSPEL and GAPDH is time
dependent (Figure 2E). Following NMDA treatment, S-nitrosy-
lated GOSPEL (SNO-GOSPEL) is detected as early as 3 hr and
peaks at 9–16 hr, whereas GAPDH S-nitrosylation is not evident
until 6 hr and continues to increase between 9 and 16 hr. We
wondered whether the S-nitrosylation of GOSPEL might reflect
trans-nitrosylation from GAPDH. This is unlikely, as incubation
of S-nitrosylated GAPDH with GOSPEL fails to elicit augmented
S-nitrosylation of GOSPEL (Figure S2D).
GOSPEL contains a single cysteine at position 47 (C47), which
conforms to an S-nitrosylation motif, as the glutamate immedi-
ately following C47 resembles the pattern for numerous S-nitro-
sylated proteins (Kim et al., 1999) including hemoglobin, ras,
NMDA receptor, and dynamin. S-nitrosylation of GOSPEL is
abolished by replacing the cysteine with serine (GOSPEL-
C47S), indicating that this single amino acid is the site forS-nitro-
sylation of GOSPEL (Figure 2F). S-nitrosylation at C47 is crucial
for GOSPEL binding to GAPDH, as their binding is greatly
reduced for GOSPEL-C47S in HEK293 cells (Figure 2G). We
have confirmed the importance of S-nitrosylation at C47 for
GOSPEL-GAPDH interaction utilizing in vitro binding of the puri-
fied proteins (Figure S3A). GAPDH S-nitrosylation occurs exclu-
sively on C150 (Hara et al., 2005). The GAPDH-C150S mutant,which cannot be S-nitrosylated, binds significantly less to
GOSPEL than the wild-type protein in HEK293 cells (Figures
S3B and S3C). Therefore, S-nitrosylation of both GAPDH and
GOSPEL is crucial for their binding (Figure 3C). Of note,
GOSPEL, SNO-GOSPEL, and Siah do not influence the catalytic
activity of wild-type GAPDH (Figures S3D and S3E).
Competition by GOSPEL and Siah for GAPDH Binding
Interaction of GAPDH and Siah occurs without S-nitrosylation of
Siah, but is augmented by S-nitrosylation of GAPDH. As both
Siah and SNO-GOSPEL can bind to S-nitrosylated GAPDH
(SNO-GAPDH), we compared the potencies of Siah and SNO-
GOSPEL in competing for binding to SNO-GAPDH (Figures S3A
andS3B). SNO-GOSPELpotently inhibits binding ofSNO-GAPDH
andSiahwith an IC50 of about 10 nM. The inhibition curve is steep,
with a decrease of maximal to minimal binding occurring over a
3-fold increase inSNO-GOSPELconcentration. Siah is lesspotent
in inhibiting the binding of SNO-GAPDH and SNO-GOSPEL, with
an IC50 of about 100 nM. The inhibition curve is also steep with
maximal to minimal binding evident over a 4-fold increase in Siah
concentration. Different portions of GAPDH respectively bind to
GOSPEL and Siah (Figures 1A and 2B). To determine whether
GOSPEL and Siah nonetheless compete for binding to GAPDH,
we overexpressed GOSPEL, Siah, and GAPDH in HEK293 cells
(Figure 3C). Overexpression of GOSPEL markedly diminishes the
binding of GAPDH to Siah in the presence of the NO-donor
GSNO. Moreover, purified GST-GOSPEL blocks protein interac-
tions ofGAPDHandHis-Siah in the presenceofGSNO (FigureS4).
NMDA also enhances GAPDH-GOSPEL interactions more
rapidly than GAPDH-Siah binding (Figure 3D). GAPDH-GOSPEL
binding is detectable under basal conditions, with increases
evident by 3 hr after NMDA. By contrast, GAPDH-Siah binding
is absent basally and is not detected until 9 hr after NMDA.
The differential kinetics of GAPDH-GOSPEL binding from
GAPDH-Siah binding may reflect more rapid S-nitrosylation of
GOSPEL (required for GAPDH-GOSPEL binding) than of GAPDH
(required for GAPDH-Siah binding) (Figure 2E).
GOSPEL Prevents the Nuclear Translocation of GAPDH
To ascertain whether endogenous GOSPEL modulates GAPDH-
Siah interactions, we depleted endogenous GOSPEL from
primary neuronal cultures of cerebral cortex utilizing RNA inter-
ference (RNAi) conveyed by a lentivirus. To rule out the possibility
of ‘‘off-target’’ effects of RNAi, we carried out quantitative real-
time PCR for 2050-oligoadenylate synthetase (OAS1), which
monitors such off-target effects (Figure S5A). The control and
GOSPEL RNAi treatment has no influence on the levels of
OAS1 mRNA. Furthermore, such RNAi treatment does not affect
the levels of nNOS and NO generated in response to NMDA
treatment in neurons (Figures S5B–S5D). The RNAi to GOSPEL
reduces the endogenous protein level by 90% (Figures S6A
and S6B). NMDA-elicited GAPDH-Siah binding is markedly
augmented in GOSPEL depleted cultures, establishing that
GOSPEL inhibits this interaction (Figure 4A).
Because Siah mediates nuclear translocation of GAPDH, we
wondered whether GOSPEL prevents such translocation and
retains GAPDH in the cytosol. Treatment of HEK293 cells with







Figure 2. GOSPEL-GAPDH Protein Interaction
(A) Schematic representation of the binding domain of GOSPEL for GAPDH. Amino acids 160–200 of GOSPEL are responsible for binding to GAPDH.
(B) Schematic representation of the interaction domain of GAPDH for GOSPEL. Amino acids 80–120 of GAPDH are responsible for binding with GOSPEL.
(C) GAPDH-GOSPEL interaction with or without NMDA exposure is diminished in primary cortical neurons from nNOS depleted mice.
(D) S-nitrosylation of GOSPEL (SNO-GOSPEL) in primary cortical neurons elicited by NMDA exposure. SNO-GOSPEL was detected by biotin switch assay as an
ascorbate-sensitive signal. Asc, ascorbate.
(E) Time course for S-nitrosylation of GOSPEL and GAPDH following NMDA treatment in primary granule neurons over 16 hr. GOSPEL is S-nitrosylated earlier
than GAPDH. S-nitrosylation of GAPDH and GOSPEL were detected by biotin switch assay.
(F) Requirement of cysteine 47 (C47) for S-nitrosylation of GOSPEL. HEK293 cells were transfected with either HA-GOSPEL or HA-GOSPEL-C47S mutant. Cells
were then treated with GSH or GSNO for 16 hr and subjected to biotin switch assay. The C47S mutant of GOSPEL is not S-nitrosylated.
(G) Requirement of cysteine 47 (C47) for efficient binding of GOSPEL and GAPDH. HEK293 cells were transfected with myc-GAPDH along with HA-GOSPEL or
HA-GOSPEL-C47S, and treated with either GSH or GSNO for 16 hr. The protein interaction was examined by coimmunoprecipitation.of GAPDH in the nucleus (Hara et al., 2005). Overexpression
of GOSPEL diminishes the nuclear localization of GAPDH
(Figure 4B). Endogenous GOSPEL also regulates the NMDA-eli-84 Neuron 63, 81–91, July 16, 2009 ª2009 Elsevier Inc.cited nuclear translocation of GAPDH, as depletion of GOSPEL
by RNAi markedly enhances nuclear GAPDH levels in neuronal
cultures (Figures 4C and S6C).
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GOSPELGOSPEL Diminishes NMDA Neurotoxicity by Preventing
GAPDH-Siah Binding
Wepreviously demonstrated that NMDAstimulation of cerebellar
granule neurons elicits NO generation from nNOS and S-nitrosy-
lation of GAPDH, which translocates to the nucleus together
with Siah and elicits neurotoxicity (Hara et al., 2005, 2006b).
We wondered whether the prevention of GAPDH-Siah binding
by GOSPEL impacts such neurotoxicity. Accordingly, we exam-
ined neurotoxicity in primary cerebellar granule neurons follow-
ing NMDA treatment (Figure 5A). Overexpression of GOSPEL
almost completely prevents the 75% decrease in neuronal




Figure 3. GOSPEL-GAPDH Binding Prevents GAPDH-Siah Interaction
(A) Inhibition of binding between S-nitrosylated GAPDH (SNO-GAPDH) and Siah by the addition of purified GOSPEL in a concentration-dependent manner. n = 3,
mean ± SEM.
(B) Inhibition of binding between S-nitrosylated GAPDH (SNO-GAPDH) and S-nitrosylated GOSPEL (SNO-GOSPEL) by the addition of purified Siah in a concen-
tration-dependent manner. n = 3, mean ± SEM.
(C) Decreased GAPDH-Siah interaction in the presence of GOSPEL. HEK293 cells were transfected with HA-GOSPEL and/or myc-Siah constructs and then
treated with GSH or GSNO for 16 hr. Cell lysates were coimmunoprecipitated by anti-myc antibody, and endogenous GAPDH was detected by anti-GAPDH
antibody.
(D) Contemporaneous measurement of binding between GAPDH and GOSPEL as well as GAPDH and Siah in primary neurons 16 hr following NMDA treatment.Neuron 63, 81–91, July 16, 2009 ª2009 Elsevier Inc. 85
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GOSPEL200 amino acids of GOSPEL (GOSPEL-DN200), which prevents
binding to GAPDH, abrogates the protective effect of GOSPEL.
By contrast, deleting the N-terminal 160 amino acids (GOSPEL-
DN160), which does not impair GOSPEL-GAPDH binding,
preserves the protective actions of GOSPEL. S-nitrosylation of
GOSPEL, which is crucial for binding to GAPDH, is also required
for the neuroprotective actions of GOSPEL. Thus, GOSPEL-
C47S, which cannot be S-nitrosylated and which does not
bind to GAPDH robustly, fails to exert a strong neuroprotective
action.
To determine whether endogenous GOSPEL influences
neurotoxicity, we employed lentivirus-mediated RNAi to deplete
endogenous GOSPEL in primary cerebellar granular cells and




Figure 4. GOSPEL-GAPDH Binding Prevents GAPDH-Siah Interaction
(A) GOSPEL depletion augments GAPDH-Siah binding in primary neuronal cultures after NMDA exposure. Neuron extracts were immunoprecipitated with
anti-Siah antibody, and immunoprecipitates were analyzed with SDS-PAGE followed by western blotting with anti-GAPDH antibody.
(B) Blockade of GAPDH nuclear translocation by GOSPEL. HEK293 cells were transfected with mock or HA-GOSPEL constructs followed by treatment with
200 mM GSNO for 16 hr, and immunostained with anti-HA (GOSPEL) and anti-GAPDH antibodies. Representative confocal images are shown. Red, GAPDH;
green, HA (GOSPEL); blue, DAPI for nucleus. The scale bar represents 40 mm.
(C) GOSPEL depletion enhances nuclear GAPDH levels in primary neuronal cultures after NMDA exposure. Neurons were separated into cytosolic and nuclear
fractions. Nuclear GAPDH levels were increased in GOSPEL RNAi-treated cells. Anti-histone H2B and anti-actin antibodies were used as nuclear and cytosolic
markers, respectively.86 Neuron 63, 81–91, July 16, 2009 ª2009 Elsevier Inc.
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GOSPELtriggered excitotoxicity, a widely employed model of neurotox-
icity (Bonfoco et al., 1995; Dawson et al., 1996) in which
GAPDH-Siah is a mediator (Hara et al., 2005, 2006b). Both at
12 and 24 hr following NMDA treatment, cell survival is substan-
tially reduced in GOSPEL depleted cultures (Figures 5B and 5C;
Figures S7A and S7B).
GOSPEL Is Neuroprotective in Intact Mice
Earlier we demonstrated that treatment with the neurotoxin
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) augments
the binding of GAPDH to Siah in mouse corpus striatum (Hara
et al., 2006b; Sen et al., 2008). Utilizing a similar paradigm, we
show that MPTP treatment stimulates striatal S-nitrosylation of
both GAPDH and GOSPEL (Figure S8A). MPTP treatment also
stimulates the binding of GAPDH-GOSPEL as well as GAPDH-
Siah, with the increased interaction of GAPDH-GOSPEL occur-
ring earlier than that of GAPDH-Siah (Figure S8B).
To determine whether neuroprotective actions of GOSPEL are
evident in intact mice, we utilized a viral vector system that
delivers into the cerebral cortexwild-typeGOSPEL andGOSPEL
lacking the N-terminal 200 amino acids (GOSPEL-DN200, which
does not bind GAPDH). The two GOSPEL constructs display
A
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Figure 5. Modulation of NMDA-Mediated Neurotoxicity by GOSPEL
(A) Overexpression of GOSPEL protects neurons from excitotoxicity in a GAPDH-GOSPEL interaction-dependent fashion. Primary cerebellar granule neurons
were transfected with or without various GOSPEL constructs (wild-type, DN160, DN200, and C47S). Cell viability was measured 24 hr after transient exposure
to 300 mM NMDA. *p < 0.01, n = 3, one-way ANOVA, mean ± SEM.
(B) Depletion of GOSPEL enhances NMDA-mediated cytotoxicity of cortical neurons. Transfection of GOSPEL RNAi in primary cortical neurons elicits a high level
of neurotoxicity 12–24 hr after treatment with NMDA. *p < 0.01, n = 3, one-way ANOVA, mean ± SEM. The scale bar represents 20 mm.
(C) Depletion of GOSPEL enhances NMDA-mediated cytotoxicity of cerebellar granule neurons. Transfection of GOSPEL RNAi in primary granule neurons elicits
a high level of neurotoxicity 12–24 hr after treatment with NMDA. *p < 0.01, n = 3, one-way ANOVA, mean ± SEM.Neuron 63, 81–91, July 16, 2009 ª2009 Elsevier Inc. 87
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GOSPELsimilar levels of expression in the cerebral cortex monitored by
western blotting (Figure 6A) and immunohistochemical staining
(Figure 6B). Neurotoxicity was elicited by direct injection of
NMDA into the cerebral cortex (Figures 6C and 6D). NMDA-
induced lesions in brains of GOSPEL-overexpressed mice are
about 30% smaller than in those injected with GOSPEL-DN200.
Thus, GOSPEL overexpression in the cerebral cortex leads to
selective diminution of NMDA neurotoxicity in vivo. The neuro-
protective influence of GOSPEL is attributable to its binding to
GAPDH, as a mutant GOSPEL which does not bind GAPDH
displays diminished neuroprotective action.
DISCUSSION
In this study we report a protein, GOSPEL, which physiologically
binds GAPDH. S-nitrosylation of GOSPEL augments GAPDH-
GOSPEL binding, which competes with the interaction of
GAPDHwith Siah. This competition prevents the nuclear translo-
cation of GAPDH and associated neurotoxicity (Figure S9).
GOSPEL is a hydrophilic protein that contains 406 amino acids
and appears to be exclusively cytosolic. It lacks obvious func-
tional motifs such as nuclear export and import signals. GOSPEL
mRNA and protein levels are highest in organs most enriched in
A B
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Figure 6. Prevention of NMDA-Induced Toxicity in Brains Expressing Wild-Type GOSPEL, but Not GOSPEL-DN200 Deficient in GAPDH
Binding
(A) Lentivirus-mediated overexpression of GOSPEL and GOSPEL-DN200 in the right cortex of C57BL/6 mouse brain. Proteins are expressed at similar levels for
the same amount of viral particles.
(B) Lentiviral vectors encoding either for HA-GOSPEL or HA-GOSPEL-DN200 were stereotaxically injected in the right cortex of mice. Sections were immuno-
stained with a polyclonal anti-HA antibody, revealing a significant overexpression of GOSPEL and GOSPEL-DN200 in the injected hemisphere. The scale bar
represents 100 mm.
(C) Representative micrographs of mouse brain sections injected with NMDA into the right cortex at the site of viral particle injection. Brains were stained with
cresyl violet. Lesions are indicated by dotted lines.
(D) Quantitative analysis of NMDA-elicited brain damage. Lesion volume was 31% ± 4% smaller in mice treated with GOSPEL than GOSPEL-DN200. Lesion
volumes are reported as mean ± SEM.88 Neuron 63, 81–91, July 16, 2009 ª2009 Elsevier Inc.
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GOSPELGAPDH, such as brain, heart, lung, and skeletal muscle. This is
consistent with the notion that GOSPEL physiologically modu-
lates GAPDH functions. By contrast, Siah levels are similar in
all organs examined.
GOSPEL retains GAPDH in cytosol, as its depletion augments
the nuclear translocation of GAPDH that is associated with cell
stress. GOSPEL’s neuroprotective actions are robust, as the
75% reduction in viability of cortical neurons elicited by NMDA
is reversed by overexpression of GOSPEL in a fashion indicating
that its neuroprotective actions derive from its binding GAPDH.
In turn, depletion of GOSPEL increases NMDA neurotoxicity.
S-nitrosylation in response to NMDA occurs more rapidly
for GOSPEL than GAPDH. Conceivably, this is relevant to the
dynamics of cellular responses to nitrosative stress. Thus,
perhaps a more rapid initiation of cytoprotective (GOSPEL
S-nitrosylation) than cytotoxic (GAPDH S-nitrosylation) mecha-
nisms reflects the cell’s approach to coping with nitrosative
stress. The more rapid response of GOSPEL to NO suggests
that itmayhavephysiologic aswell aspathophysiologic functions.
Deprenyl and related neuroprotective drugs very potently
prevent GAPDH S-nitrosylation and its binding to Siah (Hara
et al., 2006b). We speculate that GOSPEL and deprenyl act at
similar sites on GAPDH. Thus, GOSPEL binds to amino acids
80–120 of GAPDH, which contains the Rossmann fold (Nagy
and Rigby, 1995). The blockade of GAPDH-Siah binding by
deprenyl in vitro requires the presence of NAD+, which physio-
logically interacts with the Rossmann fold (M.R.H., A.S., and
S.H.S., unpublished data). These observations raise the possi-
bility that drugs mimicking GOSPEL might exert neuroprotective
actions similar to those of deprenyl.
Heretofore, studies of theNO-GAPDH-Siah/GOSPEL cascade
have focused upon cyto/neurotoxicity. However, it is likely that
this signaling system possesses physiologic roles. Thus,
GAPDH-GOSPEL binding is detectable in untreated cerebral
cortical cultures with the binding diminished in nNOS depleted
cultures or cultures treated with the NMDA antagonist MK801
(data not shown). Nuclear translocation of GAPDH may convey
signals from neuronal activity to epigenetic controls of gene tran-
scription bymodulating p300/CBP-mediated histone acetylation
(Sen et al., 2008), which may be regulated by GAPDH-GOSPEL
interactions.
EXPERIMENTAL PROCEDURES
Unless otherwise noted, all data are representative of three individual experi-
ments.
Chemicals, Antibodies, Plasmids, Overexpression, and RNAi Virus
Unless otherwise noted, chemicals were purchased from Sigma. Protein G
and A agaroses were purchased from Oncogene. Antibodies were obtained
from the following companies: anti-GAPDHmonoclonal antibody fromBiogen-
esis; anti-histone H2B antibody and anti-actin antibody from Upstate; anti-HA
antibody from Babco; anti-Myc antibody from Calbiochem; anti-nNOS anti-
body fromBDPharmingen; anti-HAantibody fromCovance; anti-Siah antibody
from Santa Cruz; and anti-GFP antibody, anti-mouse Ig conjugated to FITC,
and anti-rabbit Ig conjugated to rhodamine fromMolecular Probes. Polyclonal
antibody against GOSPELwas generated with the following procedures: GST-
taggedGOSPELwas produced inEscherichia coli, purified through glutathione
Sepharose beads (Pharmacia Biotech), and used for antigen. Antisera were
produced by a service of Research Genetics, and the sera were immunopuri-fied. Constructs expressing site-directed or deletion mutant proteins were
prepared according to the published protocol (Ho et al., 1989).
GOSPEL RNAi mediated by a lentiviral system (target sequence:
50-AAGGCTCTGATTGAGCAGAAG-30) was generated as follows: the target
sequences were cloned in the pFUGW vector, and this construct was trans-
fected in HEK293FT cells along with two other helper/packaging vectors
(D8.9 and VSVg constructs) to produce lentiviral particles. For the production
of control lentivirus, FUGW vector was transfected into HEK293FT cells along
with two other helper/packaging constructs. Viral production was allowed to
take place for 48–72 hr inside HEK293FT cells, and the supernatant was
collected and ultracentrifuged to bring down viral particles, which were resus-
pended in OPTI-MEM. About 106–107 pfu/ml viruses was infected in primary
neurons for 24 hr. Viral expression was confirmed by observing GFP encoded
in pFUGW backbone 5 days after infection. Wild-type HA-GOSPEL and
HA-GOSPEL-DN200 expression by a lentiviral system was prepared as
follows: both inserts were cloned in pENTR/D-TOPO vector (Invitrogen), and
then inserted in pLenti4/TO/V5-DEST vector (Invitrogen) individually by homol-
ogous recombination (according to the manufacturer’s protocol). The final
constructs were transfected in HEK293T cells along with two other helper/
packaging vectors (D8.9 and VSVg constructs), and the supernatant was
collected and ultracentrifuged to bring down viral particles, which were resus-
pended in OPTI-MEM. About 107–108 pfu/ml viruses was infected in primary
neurons for 24 hr. Viral expression was confirmed by western blotting with
an HA antibody 5 days after infection.
Yeast Two-Hybrid and cDNA Library Screenings
The N-terminal amino acids 1–150 of rat GAPDH open reading frame were
cloned into yeast expression vector pPC97 containing the Gal4 DNA binding
domain. These constructs were used for the screening of a rat hippocampal
cDNA library cloned into pPC86 containing the Gal4 transactivation domain.
An adult rat brain cDNA library in l ZAPII vector (Stratagene) was screened
using the yeast two-hybrid fragment for a portion of GOSPEL open reading
frame, labeled with [32P]dCTP using a random priming DNA-labeling kit (Boeh-
ringer Mannheim). A total of 13 106 clones was screened, yielding 61 overlap-
ping clones.
Northern Blotting and In Situ Hybridization
Rat GOSPEL cDNA fragment utilized as a probe was labeled with [32P]dCTP
using the High Prime DNA-labeling system (Roche Diagnostics), and northern
hybridization was performed at 68C for 2 hr in QuikHyb solution (Stratagene)
with a tissue mRNA blot membrane (Clontech) (Burnett et al., 1998).
Biochemical Studies
In vitro binding experiments were performed according to the published
protocol with glutathione Sepharose (Bae et al., 2005; Kamiya et al., 2005).
Coimmunoprecipitation and western blotting were conducted as published
previously (Bae et al., 2005; Kamiya et al., 2005). Subcellular fractionation
was carried out with a nuclear/cytosol fractionation kit (BioVision). An S-nitro-
sylation biotin switch assay was conducted as published previously (Forrester
et al., 2007; Jaffrey and Snyder, 2001). Trans-nitrosylation assay was per-
formed as follows: purified wild-type GAPDH (1.5 mg) purchased from Sigma
was incubated with 200 mMGSNO at 37C for 1 hr. The whole reaction mixture
was then passed through a desalting column (Pierce) to remove free GSNO.
S-nitrosylation of GAPDH was confirmed by biotin switch assay. For the
trans-nitrosylation reaction, 0.1, 1.0, or 2.5 mg of GST-GOSPEL was incubated
with S-nitrosylated GAPDH at 4C for 1 hr with mild rotation in 1 ml of buffer
(50 mM Tris [pH 7.4], 150 mM NaCl, 0.1 mg/ml BSA, and 0.1% CHAPS). The
whole solution was used for the biotin switch assay to detect S-nitrosylation
of GOSPEL protein.
In a cell-free binding assay, we purified GAPDH, GOSPEL, and Siah protein
separately. GAPDH and GOSPEL were incubated separately with 200 mM
GSNO at 37C for 1 hr. The whole reaction mixture was then passed through
a desalting column (Pierce) to remove free GSNO. Then SNO-GAPDH and
SNO-GOSPEL were mixed at a 1:1 molar ratio. GST-Siah was added in
a concentration-dependent manner (0–500 nM) and kept at 37C for 1 hr. In
another set of experiments, we incubated SNO-GADH and Siah along with
different concentrations of GST-GOSPEL (0–100 nM) at 37C for 1 hr. ThenNeuron 63, 81–91, July 16, 2009 ª2009 Elsevier Inc. 89
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measuring the optical density of GAPDH, we calculated IC50 values for inhibi-
tion of binding between GAPDH and GOSPEL by Siah as well as binding
between GAPDH and Siah by GOSPEL.
For quantitative PCR, total RNA was isolated from granule neurons with the
RNeasy mini kit (QIAGEN) and was reversely transcribed with the Omniscript
RT kit (QIAGEN). Real-time PCR was performed using SYBR green PCR
master mix for OAS1. The primers used for OAS1 amplification are as follows:
forward primer for OAS1 is 50-CCATCCTCAAGTGGACAAGAACTG-30; reverse
primer for OAS1 is 50-TTGGGCTTTGGGCACCTTC-30 (Bridge et al., 2003).
Enzymatic Assay for GAPDH
GAPDH (10 nM) or S-nitrosylated GAPDH were preincubated with either
GOSPEL (100 nM) or Siah (500 nM) at 37C for 30min. S-nitrosylated GOSPEL
(100 nM) was also preincubated separately with 10 nM GAPDH or S-nitrosy-
lated GAPDH in the presence or absence of Siah at 37C for 30 min. The assay
mixture was added to each tube and the incubation continued at 37C for
10 min. The assay mixture contained 10 mM sodium pyrophosphate (pH 8.5),
20 mM sodium arsenite, 2 mMNAD+, and 2 mM glyceraldehyde-3-phosphate.
Optical density was measured at 340 nm. All values are normalized to control
and expressed as arbitrary units.
Cell Culture and Staining
HEK293 cells and HEK293FT cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% FBS and 2 mM L-glutamine at 37C with
a 5% CO2 atmosphere in a humidified incubator. PC12 cells were maintained
in DMEM with 10% FBS, 5% horse serum, 2 mM L-glutamine, and 100 U/ml
PS in the same environment. Primary cortical neuronswere prepared from fetal
mice (14 day gestation) derived from wild-type and nNOS knockout mice, and
cultured in neurobasal media supplemented with B27, 2 mM L-glutamine, and
100 U/ml PS at 37C with a 5% CO2 atmosphere in a humidified incubator.
Cerebellar granule neurons were prepared from neonatal mice and cultured
in basal Eagle’s medium containing 10% FBS, 25 mM KCl, and 2 mM L-gluta-
mine. Immunocytochemistry using confocal microscopy was performed as
described (Sawa et al., 1999). Confocal microscropy images were obtained
using a Zeiss Meta confocal system. For neuron cultures, anti-GFP antibody
was used to enhance the signal from transfected cells.
Measurement of NMDA-Induced Neurotoxicity in Primary Neurons
To activate NMDA receptors in neurons, 8- to 10-day-old cultures (DIC 8-10)
were treated with Mg2+-free Earle’s balanced salt solution containing 300 mM
NMDA and 5 mM glycine for 10 min.
Three days prior to NMDA receptor activation, cerebellar granule neurons
were transfected with plasmids as follows: after preincubation of cells with
neurobasal media (GIBCO BRL) including B27 for 24 hr from DIV 5, neurons
were transfectedwith 1 mg of GFP construct and a total of 3 mg of varied combi-
nations of plasmids using Lipofectamine 2000. The molar ratio of expression
constructs toGFPplasmidwas 3:1. Using fluorescentmicroscopywith a digital
camera, we captured images of more than 20 fields per preparation, which
were randomly chosen in a blind manner. GFP-positive neurons were tallied
in each field and added together to determine the percentage of viable cells
compared to control.
Three days prior to NMDA receptor activation, RNAi lentivirus was infected
into granule or cortical neurons. Viability of neurons was assayed 12 or 24 hr
after exposure to NMDA as follows: cells were washed with PBS and incu-
bated in 1 mg/ml propidium iodide for 10 min (dead cells are stained in red).
After extensive washing to remove nonspecifically attached propidium iodide
to cell debris by PBS, neurons were then fixed in 4% paraformaldehyde (PFA)
in PBS and stained with DAPI to visualize the total cell population. As the
majority of neurons were infected, the ratio of propidium iodide-stained cells
to DAPI-stained cells was employed to reflect toxicity.
Measurement of Nitric Oxide Species
To measure the reactive nitric oxide level inside cells, we used 4,5-diamino
fluorescein diacetate (DAF-FM;Molecular Probes), a cell-permeable derivative
of the indicator DAF-2 whose fluorescence reflects the level of endogenous
nitric oxide (Choi et al., 2000; Chvanov et al., 2006). Briefly, neurons were90 Neuron 63, 81–91, July 16, 2009 ª2009 Elsevier Inc.washed once with Hank’s balanced salt solution (HBSS) and then loaded
with 5 mMDAF-FM in HBSS and incubated at 37Cwith a 5%CO2 atmosphere
in a humidified incubator for 60 min. NMDA (300 mM) and glycine (5 mM) were
added to the cells and incubated for another 10 min. Cells were washed and
harvested in HBSS, and fluorescence was measured in a fluorimeter utilizing
excitation at 485 nm and emission at 530 nm. DAF-2 fluorescence was also
detected using a laser scanning confocal microscope (Zeiss Meta).
Animals and MPTP Treatment
All experimentswere approved and conformed to the guidelines set by the Insti-
tutional Animal Care Committee. Eight-week-old male CD1 mice (Jackson
Laboratory)wereused.Mice received four i.p. injectionsofMPTP-HCl (20mg/kg
free base; Sigma) in saline at 2 hr intervals and were sacrificed 16 and 24 hr
after the first injection (n = 5). Control mice received saline only. In each case
the striatum was isolated and used for immunoprecipitation and S-nitrosylation
experiments (Hara et al., 2006b).
Stereotaxic Injection into Intact Mice
Adult male C57BL/6 mice (20–25 g; Charles River) were used for NMDA-medi-
ated cytotoxicity measurement. Animal protocols, approved by the Institu-
tional Animal Care and Use Committee of Johns Hopkins University, were
used in accordance with the National Institutes of Health Guidelines for the
Care and Use of Laboratory Animals. Animal well-being was determined by
monitoring weight and rectal temperature before the surgical procedure.
Mice were anesthetized with 3.0% isoflurane, maintained with 1.0% isoflur-
ane, and mounted on a stereotaxic frame (Stoelting). The skull was exposed
and 5.0 ml (107–108 pfu/ml) of viral particles of either full-length GOSPEL (n = 8)
or DN200 GOSPEL (n = 9) protein was slowly injected into the cortex (anterior
0.5 mm, lateral 3.5 mm from bregma, and ventral 1.0 mm relative to dura)
over a period of 20 min with the help of a 5.0 ml Hamilton syringe, and the
needle was left in place for an additional 5 min. Seven days after viral infection,
overexpressed full-lengthGOSPEL orDN200GOSPEL in coronal sections was
detected by western blot and immunohistochemistry with anti-HA antibody
(1:200). On day 8, 15 nmol NMDA was slowly injected at the same location
with a 1.0 ml Hamilton syringe. After each injection, mice were placed in a ther-
moregulated chamber maintained at 31C ± 0.5C and returned to their cages
after full recovery from anesthesia. The rectal temperatures were monitored
and maintained at 37.0C ± 0.5C during the experimental procedure.
NMDA-Induced Lesion Quantification
At 24 hr post-NMDA injection, mice were trancardially perfused with 0.1 M
PBS and fixed with 4% PFA. Brains were harvested and soaked in 4% PFA
overnight, and then equilibrated with 30% sucrose. Sequential brain sections
of 25 mm obtained on cryostat were stained with cresyl violet to estimate the
lesion volume as described previously (Ahmad et al., 2006, 2007). One-way
ANOVA followed by Tukey’s post-hoc analysis was used to calculate the
difference between the groups.
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